Abstract
Olfactory ensheathing cell (OEC) transplantation is emerging as a promising treatment option for injuries of the nervous system. OECs can be obtained relatively easily from nasal biopsies, and exhibit several properties such as secretion of trophic factors, and phagocytosis of debris that facilitate neural regeneration and repair. But a major limitation of OEC-based cell therapies is the poor survival of transplanted cells which subsequently limit their therapeutic efficacy. There is an unmet need for approaches that enable the in vitro production of OECs in a state that will optimize their survival and integration after transplantation into the hostile injury site. Here, we present an overview of the strategies to modulate OECs focusing on oxygen levels, stimulating migratory, phagocytic, and secretory properties, and on bioengineering a suitable environment in vitro.
Introduction
The olfactory system has a unique neurogenic niche in which olfactory sensory neurons are replaced throughout an individual’s lifespan. Because the olfactory neuroepithelium is exposed to the external environment, there is a constant turnover of olfactory neurons, and newborn olfactory neurons are supported and guided by specialized glia called olfactory ensheathing cells (OECs). OECs are located in the lamina propria underlying the olfactory mucosa and surround the axons of the olfactory sensory neurons from the epithelium up into the nerve fiber layer of the olfactory bulb1–3. Thus, OECs can be easily obtained from an intranasal biopsy of the olfactory mucosa including the lamina propria. OECs share morphological and molecular features with both central nervous system (CNS) glia such as astrocytes, and peripheral glia such as Schwann cells4–6. They support the continual regeneration of neurons by acting as a suitable substrate, and by migrating in tandem or ahead of emerging olfactory axons7–9. OECs are also considered to be the primary innate immunocytes in the olfactory system. They are a dynamic cell population that can be stimulated from a resting state to a phagocytic state, and they are capable of clearing bacteria and axonal debris10,11. Due to their numerous properties, the transplantation of OECs to repair injuries in other regions of the nervous system, particularly spinal cord injury (SCI), is being explored by many research groups.
An injury to the spinal cord is devastating and often an irreversible event that usually triggers multiple deleterious processes such as delayed and progressive cell death, ischemia, hypoxia, inflammation, and extensive scarring 12 . This complex injury site microenvironment is pro-apoptotic and anti-regenerative 13 . To overcome these inhibitory factors, OECs have been trialed extensively for SCI repair because of their versatile and favorable biological functions which can ameliorate the environment of the injury site and promote regeneration. OECs can offer neuroprotection, enhance neurite outgrowth, provide axonal guidance cues, and promote remyelination in animal models and in humans (reviewed in Gómez et al. 14 ). Despite several completed clinical trials with transplantation of OECs demonstrating safety and efficacy, the recovery outcomes in patients are often variable. While there are multiple factors contributing to the variable recovery outcomes such as differences in cell source, cell purity, cell delivery techniques, and assessment of functional readouts (reviewed in Kawaja et al. 15 , Miah et al. 16 , Yao et al. 17 ), a consistent observation across studies has been the poor survival of transplanted cells, with the reported survival rates of transplanted OECs being as low as 0.3% to 3% in animal models18–21. To compensate for this massive cell loss post-transplantation, excess cells are transplanted into the injury site. However, this approach comes with limitations as it introduces additional cytotoxic products (apoptotic corpses) at the injury site without any improvement in viability. In addition, it is not always feasible to produce a surplus of cells for autologous therapies due to the limitations in cell production from a small biopsy source material. While the majority of our knowledge on OEC biology comes from using rodent olfactory tissues, OECs have also been isolated and purified from different species such as dogs, pigs, primates, and humans22–26. There are fundamental inter-species differences in the control of OEC proliferation and their response to different growth factors (reviewed in Wewetzer et al. 27 ). To overcome the complexities in culturing OECs from different species, it is important to identify and maintain cells under optimal conditions that favor cell proliferation and rapid expansion while maintaining cell-specific properties such as morphology, antigen expression, and phagocytosis. For OECs to be used clinically for cell transplantation, it will be imperative to produce sufficient purified cells in a short timeframe in vitro. Therefore, it is critical to test protocols for cell isolation, purification, and expansion for OECs obtained from individual species to predetermine optimal culture conditions, rather than assume cells from different species will respond similarly.
Strategies need to be designed that enable the in vitro production of OECs in a state that will optimize their survival and integration after transplantation into the hostile injury site. However, commonly used in vitro models for cell expansion do not reflect the conditions of the injury site and this critical aspect of the OEC transplantation therapy is mostly unexplored. By implementing pretreatment strategies for the culture of OECs in an environment mimicking the host site before transplantation, their phagocytic, secretory, and migratory capacity can be improved to enhance viability and neural regeneration at the transplantation site. This review focuses on the following themes prior to cell transplantation of OECs: (1) homeostatic/hypoxic preconditioning and (2) priming/activating cells, and (3) bioengineering a suitable microenvironment.
Homeostatic/Hypoxic Preconditioning of OECs
Oxygen availability is a fundamental requirement for cellular function, and decreased oxygen levels can induce cellular stress. Under homeostatic conditions, cells require oxygen levels between 2% and 9% (14.4–64.8 mm Hg), whereas lower oxygen levels 0.5% to 2% (<10 mm Hg) are considered hypoxic 28 . Standard cell culture practice involves culturing cells in liquid medium incubated at atmospheric oxygen levels of 21% which is considerably higher than physiological oxygen levels. Continued exposure to oxygen concentration above physiological levels can lead to premature senescence of primary cells29,30. It is likely that cells are physiologically adapted to their anatomic niche conditions. By culturing cells ex vivo under higher oxygen levels and then transplanting them in vivo to homeostatic or hypoxic conditions, the cells may require significant re-adaptation which may confer additional cellular stress. This may be a contributing factor to the poor survival of OECs after transplantation. Hence, there is a need for in vitro approaches to mimic the low oxygen conditions that the cells experience in their tissue-specific niche and the transplantation site.
To gain insight into the potential for homeostatic oxygen or hypoxic preconditioning where cells are cultured under low oxygen conditions, it is useful to examine how other cells respond, such as mesenchymal stem cells (MSCs; Table 1). The aims of homeostatic/hypoxic preconditioning are to improve the viability of the cell product and the therapeutic properties of the transplanted cells. Culturing bone marrow–derived mesenchymal stem cells (BM-MSCs) in hypoxic conditions has been shown to increase proliferation, multipotency, and the secretion of cytoprotective molecules49,52. This has partly been attributed to the provision of oxygen levels similar to the resident cellular niche. The cellular niche encompasses the local microenvironment that includes both cellular and acellular components that nourish and regulate the functions of cells. Oxygen levels in the niches of mesenchymal and neural stem cells are 2% to 8% and 1% to 8%, respectively53,54.
Effect of Hypoxia on Therapeutic Potential of Mesenchymal Stem Cells.
OM-MSC: olfactory mucosa–mesenchymal stem cell; HIF-1α: hypoxia-inducible factor 1-alpha; VEGF: vascular endothelial growth factor; GDNF: glial-derived neurotrophic factor; BDNF: brain-derived neurotrophic factor; NGF: nerve growth factor; BM: bone marrow; SCI: spinal cord injury; UC: umbilical cord.
Olfactory mucosa–mesenchymal stem cells (OM-MSCs) are a type of Nestin-positive stem cells identified 55 in the olfactory mucosa that have the potential to differentiate into smooth muscle cells, adipocytes, osteocytes, and neurons and show similar antigenic profile to BM-MSCs56,57. The OM-MSCs secrete anti-inflammatory cytokines and have been shown to improve myelination of rat spinal cord cell cultures 58 . Due to these favorable properties, OM-MSCs are an alternative source of MSCs for autologous cell transplantation. OM-MSCs and OECs are resident within the same niche, the highly cellular lamina propria (reviewed in Lindsay et al. 59 ). The application of conditions tested on OM-MSCs to OECs can be an appropriate strategy to re-create an optimized microenvironment for the culture and expansion of OECs, and to improve their efficacy for cell transplantation.
Similar to BM-MSCs, hypoxic preconditioning of OM-MSCs resulted in increased secretion of neuroprotective paracrine factors against cerebral ischemia/reperfusion injury. Interestingly, hypoxic OM-MSCs were able to inhibit microglial cell death following cerebral ischemia/reperfusion injury in vitro. This anti-pyroptotic and anti-apoptotic effect of OM-MSCs on microglia was mediated by regulating expression levels of hypoxia-inducible factor 1-alpha (HIF-1α), a key transcription factor regulating cellular response to hypoxia34,33. Preconditioning of OM-MSCs resulted in marked increase of HIF-1α, and silencing HIF-1α in OM-MSCs affected cell viability and resulted in acceleration of apoptosis 32 . A hypoxic environment could also promote differentiation of OM-MSCs to dopaminergic neurons by upregulation of HIF-1α and activation of tyrosine hydroxylase35,60. Thus, it is clear that MSCs respond in various ways to low oxygen conditions and hence the effect of low oxygen conditions should be considered for OECs.
Survival of OECs in culture and at the transplantation site can be compromised by a lack of oxygen and nutrients to support their viability. In vitro sensitivity of OECs to hypoxia and serum deprivation was tested by Pellitteri et al., in neonatal mouse OEC cultures. OEC proliferation and survival were reduced when exposed to a combination of hypoxia and serum starvation 61 . Addition of basic fibroblast growth factor, a mitogen for OECs 62 , could improve survival and proliferation of OECs from hypoxia or serum deprivation. Intriguingly, the growth rate of primate OECs was unaffected by environmental oxygen concentration in contrast to rodent OECs which appeared to overcome replicative senescence when cultured in low oxygen conditions 25 .
A recent study 63 investigated the therapeutic effects of exosomes from human umbilical cord–derived MSCs on OECs in hypoxic conditions for sciatic nerve regeneration in rats. Treating OECs with exosomes resulted in improved viability, proliferation, and migration of OECs, and increased the secretion of brain-derived neurotrophic factor (BDNF) thereby resulting in improved functional recovery in injured rats. Notably, extracellular vesicles derived from hypoxia-preconditioned OM-MSCs (3% O2) could promote HIF-1α–vascular endothelial growth signaling in human brain microvascular endothelial cells via miR-612 upregulation and downregulation of TP53, a component of cellular stress responses, resulting in enhanced angiogenesis in in vitro tube formation assays 31 .
While these studies make a case for preconditioning cells to low oxygen conditions before transplantation into a “hostile” hypoxic environment, the adoption of low oxygen pretreatment to a clinical setting will be contingent on the protocol consistency. It will be critical to predetermine the vulnerability and responses of the OEC cellular product to hypoxic stress, the duration and percentage O2 of low oxygen exposure, and ultimately the ideal conditions to improve cell survival and integration at the transplantation site.
Pretransplantation Cell Priming
The inflammatory environment and the inhibitory extracellular matrix at the injury site in the CNS result in poor growth conditions for both the endogenous and transplanted cells64,65. OECs offer a potential therapeutic benefit as they can modulate the inflammatory environment, remove cell and myelin debris, and offer neurotrophic and physical support to regenerating axons (Fig. 1, reviewed in Yao et al. 17 , Brosius Lutz and Barres 66 , and Fregnan et al. 67 ). Many aspects of OECs and their cellular interactions for pro-regenerative functions have been studied in vitro using assays for neurite outgrowth, interaction with astrocytes, debris clearance, and phagocytosis assays 14 . One avenue to further improve the therapeutic efficacy of OECs is to enhance their activities. Thus, there is a need for the design of approaches to activate or train OECs to attain a functionally relevant phenotype in vitro and to retain or enhance their relevant function in vivo after transplantation.

Schematic of the various biological roles of olfactory ensheathing cells that favour neural regeneration. The therapeutic effects of olfactory ensheathing cell transplantation for neural repair are attributed to their biological roles such as phagocytosis of debris, interaction with astrocytes, neurotrophic support, immunomodulation, and neuronal regeneration.
Different approaches have been tested to stimulate the secretion of growth factors, and to enhance the migratory and phagocytic capabilities of OECs. The main objectives of cell priming or preconditioning cells by exposure to an activating/priming agent in vitro are to augment their potential therapeutic properties and to better prepare the cells to face the conditions at the transplantation site.
Soluble signaling cues
OECs secrete many neurotrophic molecules such as neurotrophin-3 (NT-3), nerve growth factor (NGF), glial-derived neurotrophic factor (GDNF), BDNF, neurotrophins-4/5 (NT-4/5), and vascular endothelial growth factor (VEGF)68–70, These molecules can also counteract the diffusion of inhibitory molecules from neuronal debris by phagocytosing debris.
To optimize the functional outcomes from OEC transplantation, cell modulation with different neurotrophins has been tested (reviewed in Rosner et al. 71 and Wright et al. 72 ). NT-3 is an interesting candidate as it can promote both the proliferation and survival of OECs, and also different groups have shown that local application of NT-3 at the injury site was favorable for regeneration after SCI73–75. To achieve long-term and site-specific delivery of NT-3 to the injury site, OECs genetically modified to secrete high amounts of NT-3 were transplanted to the injured spinal cord, and these cells could significantly improve axonal outgrowth73,76. A recent study explored the effect of NT-3 in a rat model of SCI and showed that NT-3 could inhibit the mitogen-activated protein kinase (MAPK) signaling pathway 77 . Similarly, NGF and BDNF play a neuroprotective role by modulating the MAPK/mitogen-activated extracellular signal-related kinase (MEK) pathway78,79.
The Wingless-related integration site (Wnt) signaling pathway influences multiple aspects of neural development from cell proliferation, cell fate specification, and neuronal morphogenesis to cell death (reviewed in Ciani and Salinas 80 ). A specialized subgroup of OECs in the inner nerve layer of the olfactory bulb was identified using Wnt reporter mice, and Wnt signaling was implicated in appropriate olfactory axonal targeting and in neural regeneration81–83. Notably, the activation of Wnt signaling could promote self-renewal of olfactory epithelial stem cells and neuronal differentiation. Furthermore, Wnt signaling activation is critical for the regeneration of adult olfactory epithelium after methimazole induced injury 84 . Activation of canonical Wnt signaling was shown to be both necessary and sufficient to drive the transition of horizontal basal stem cells from a resting to an activated neurogenic state in the uninjured epithelium 85 . Recently, it was reported that Wnt-activated OECs can stimulate neural stem cell proliferation and neuronal differentiation in neonatal mouse OECs. Interestingly, the conditioned medium from Wnt-activated OECs was sufficient to stimulate proliferation of neural stem cells determined by an increase in Ki67 and Sox2 double positive cells, and it could also promote the differentiation of neural stem cells into β-tubulin III positive neurons 86 .
There is growing evidence supporting a paracrine/secretory effect of transplanted cells such as MSCs and OECs on neural regeneration (reviewed in Makridakis et al. 87 ). These studies indicate that there may not be a need for homing of large cell numbers to the injury site to observe an effect. Secreted signaling cues could be sufficient to drive cellular responses, and there is potential for using activation or stimulation of the cells as another approach to enhance therapeutic potency of transplanted cells by improving their function and their resistance to inflammatory conditions. Little is known about the immunomodulatory properties of OM-MSCs. To address this, Jafari et al., compared the cytokine secretion of stimulated OM-MSCs and adipose-derived MSCs by short-term priming protocols to stimulate Toll-like receptors. Interestingly, OM-MSCs had significantly higher levels of immunosuppressive cytokines interleukin-8, transforming growth factor beta (TGF-β) and C-C motif chemokine ligand 5 secretion in comparison with adipose tissue–derived MSCs even before any treatment 88 . We recently reported that OECs produced less pro-inflammatory cytokines compared with Schwann cells and macrophages when exposed to necrotic bodies and in a pro-inflammatory microenvironment 89 . The secretome of OM-MSCs has been reported previously 90 and the results showed that the secreted proteins were mainly associated with neurotrophy, cell growth, angiogenesis, cell differentiation, and apoptosis. In cerebral ischemia reperfusion injury, models, OM-MSCs were shown to downregulate reactive oxygen species and lipid peroxidation levels, and eventually reduce neuronal apoptosis 33 . Recently, extracellular vesicles derived from OECs were shown to display neuroprotective effects on neural progenitor cells and promoted peripheral nerve regeneration in rats91,92.
Overall, these studies suggest that OECs can be stimulated in vitro to enhance the activity, function, and secretome of OECs which can then exert various benefits to other cell types. However, a robust analytical approach is required to identify the “ideal” activators for OECs and to measure the immunosuppressive potential of activated OECs in an inflammatory environment.
Migration
Transplanted cells will encounter a complex and unfavorable environment during their migration as they are faced with different cell types such as reactive astrocytes, activated microglia, invading fibroblasts, inflammatory molecules, and debris at the injury site. These interactions have the potential to modulate the transplanted cells and affect their ability to migrate. It is likely that OECs transplanted at the site of SCI will be surrounded by glial-fibrillary acidic protein-positive cells, possibly reactive astrocytes 93 , and these astrocytes can limit OEC migration. For instance, tumor necrosis factor alpha (TNFα) is secreted by reactive astrocytes at the site of injury and can modulate OEC migration in a dose-dependent fashion, blocking tumor necrosis factor receptor 1 alpha (TNFR1α). This can result in the reduced migration of olfactory bulb OECs 94 . Despite the odds being stacked against migration and integration at the injury site, OECs have been shown to migrate with the regenerating axons 95 and interact with astrocytes5,96. These migratory properties of OECs, along with their ability to interact with astrocytes at the injury site and modulation of the inflammatory environment, are thought to contribute toward favorable neural repair in the CNS5,94,97,98. Moreover, OECs can also downregulate the translocation of nuclear factor kappa beta (NFκB) in astrocytes, an important response implicated in astrocyte activation. Insulin-like growth factor-1, secreted by OECs is considered a key contributor to the modulation of astrocytes activation by OECs by potentially preventing the translocation of NFκB to astrocyte nuclei 99 .
Different candidates have been tested to stimulate OEC migration with the objective of improving neural repair outcomes. We have shown previously that OEC migration is characterized by lamellipodial waves that appear to direct intercellular interactions. The lamellipodia migration of OECs could also be enhanced by GDNF which further mediates the motility of axons100,101. Integrin alpha-7 has been reported to play an important role in the migration of adult OECs without directly affecting neurite regeneration 102 . Fibulin-3, Slit2, and NogoA have been shown to inhibit OEC migration, and interestingly they are also often found to be overexpressed in the scar tissue at lesion sites103–105. Similarly, lysophosphatidic acid (LPA) is produced at the injury site, and has been reported to promote migration and proliferation of OECs via extracellular signal-regulated kinase (ERK1/2) signaling 106 while also facilitating the homing of OECs to the injury site 107 . We recently showed that liraglutide, a glucagon-like peptide-1 receptor agonist, could stimulate OEC migration by reducing time in arrest, upregulating laminin-1, and activating the ERK pathway 108 . Another approach to augment OEC migration at the site of injury is to genetically modify cells. One such study was to modify OECs to express Nogo receptor ectodomain. These modified cells migrated longer than non-modified cells both in vitro and post-transplantation in a rat model of SCI. The myelin mediated inhibition of OEC migration could be partly overcome by treatment with NEP1-40 peptide or antibodies against Nogo receptor 109 .
These studies further support the notion that stimulating migration of OECs is feasible, and perhaps incorporating cells with enhanced migratory properties should be a consideration when designing OEC-based cell therapies for neural repair.
Phagocytosis
The persistence of cellular and myelin debris at the site of CNS injury impedes neural regeneration 110 . Effective stimulation of OEC phagocytic activity is another avenue to promote debris clearance and thereby improve neural regeneration. Accumulating evidence from our group and other studies has helped identify different compounds that can increase OEC phagocytosis, including curcumin 111 , curcumin with lipopolysaccharide (LPS) 112 , natural products 2-methoxy-1,4-naphthoquinone 113 , the serrulatane diterpenoids 3-acetoxy-7,8-dihydroxyserrulat-14-en-19-oic acid, and 3,7,8-trihydroxyserrulat-14-en-19-oic acid 114 . The anti-inflammatory cytokine TGF-β has also been implicated in increasing OEC phagocytosis 115 .
Curcumin elicits pleiotropic effects in OECs in a dose-dependent manner. In assays where neurons are co-cultured with OECs and neuronal debris, increased clearance of debris was observed in the presence of LPS and curcumin stimulus 112 or TGF-β 115 , and this in turn promoted neuronal survival. Strikingly, pretreatment with curcumin resulted in improved functional recovery and axon growth in a rat model of SCI. Cells stimulated by curcumin exhibited increased expression of phosphatidylserine receptor suggestive of increased phagocytosis and secreted more growth factors in vivo at the injury site 116 . Recently, it was shown that when activated by curcumin and LPS, OECs had pro-angiogenic effects such as promoting proliferation, migration, and vessel formation of vascular endothelial cells likely by modulating the phosphatidylinositol 3-kinase/protein kinase B pathway 117 .
Compared with Schwann cells, OECs appear to have more favorable neural repair characteristics. In addition to producing less pro-inflammatory cytokines compared with Schwann cells in a pro-inflammatory environment, we have also demonstrated that OECs phagocytosed more myelin debris than Schwann cells 89 . More data are clearly needed to understand how OECs interact with the immune and nervous systems, and how debris clearance is coordinated between OECs and professional phagocytic cells at the injury site.
Overall, these studies show that OECs are responsive to stimulation and the potential exists that these various activities can be manipulated to further enhance the therapeutic benefits of OECs after transplantation. To create a microenvironment suitable to drive axonal regeneration, we need to develop and test approaches to activate and train OECs in vitro to maximize their functions in vivo. Systematic analysis of the priming agents and optimizing the duration of priming to modulate therapeutic efficacy will be the key to achieving efficient cell therapy outcomes with minimum cell dosage and side effects.
Bioengineering a Suitable Microenvironment
Another challenge in the application of cell therapies for SCIs is the retention of biological functions of transplanted cells. For cells to function consistently as “living drugs,” we must aim to recreate or mimic their in vivo niche in a dish and to standardize cell production protocols 118 . The factors that directly or indirectly affect the cell behavior such as extracellular matrix, neighboring cells, signaling cues, and mechanical forces caused by movement of physiological fluids, all constitute the microenvironment of a cell.
OECs are conventionally cultured in vitro and expanded as adherent monolayers under conditions commonly used for mammalian cells. However, access to nutrition and oxygen is not uniform and well-controlled under these conditions, and intercellular interaction is unnatural when cells are adhered to a dish. Moreover, the properties of these cells are dependent on factors such as cell density and time in culture. Cells are also reliant on direct contact with the surrounding extracellular matrix and neighboring cells for maintenance and regulation of their biological function. So, two-dimensional adherent culture conditions are not ideal, and there is a disparity between what the cells require for performing their biological roles and what is provided in vitro. There is a need for developing models mimicking both the resident cellular niches and the transplantation niche.
Rapid advances in materials science have led to the use of different biomaterials with the aim of promoting functional tissue repair at the site of injury119,120. Provision of three-dimensional (3D) support has been shown to improve efficacy of BM-MSCs after transplantation by mimicking the cellular niche, and creating a conducive and stable environment for axonal regeneration and cell survival (reviewed in Zhou et al. 121 ).
Different biomaterials have been trialed in combination with OECs with varying success (Table 2). These biomaterials function as carriers for the cells and as structural scaffolds for axonal regrowth. The minimum prerequisites for a suitable biomaterial are biocompatibility, biodegradability, and adaptive mechanical properties. Despite the application of fabricated and synthetic 3D scaffolds such as fibrin and polymer-based scaffolds for nerve repair, there remains a need for biologically relevant scaffolds or scaffold-free 3D culture techniques. It is expected that decellularized scaffold-based tissue constructs could be directly transplanted for the regrowth of axonal tracts and to hasten the neural regeneration in vivo 144 . Decellularization is the process of creating an acellular extracellular matrix scaffold by removal of the cellular components of living tissues. These acellular scaffolds are subsequently used to provide structural and spatial support, cytokine support, and integration through cell surface molecules 145 . Spinal cord decellularized scaffolds have been shown to promote axonal regeneration and functional motor recovery in the hind limbs of rats with SCI146–148. Decellularized scaffolds seeded with OECs showed good biocompatibility with adherent and proliferating OECs observed in the scaffold, and when transplanted into rat spinal cord, the decellularized scaffold + OEC group could promote axonal regeneration and showed significant motor function recovery after 3 weeks of injury 149 . However, decellularized materials which have a fixed architecture restrict to some degree the movement and interactions of cells that are seeded into the 3D construct. Thus, the resultant cell relationships may not reflect a more natural arrangement that may occur if the cells had a less restrictive environment.
Studies Using Olfactory Ensheathing Cells–Seeded Scaffolds.
OEC: olfactory ensheathing cell; SFS: silk fibroin scaffolds; SCI: spinal cord injury; ONF: olfactory nerve fibroblasts; PLGA: poly (lactic-co-glycolic-acid); OE-MSC: olfactory ecto–mesenchymal stem cell; PCL: poly-ε-caprolactone; NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor; SPCL: starch-based polycaprolactone scaffold; C/PCL: collagen/Poly-ε-caprolactone; PU/PLDL: polyurethane/polylactide; PHB: polyhydroxybutyrate.
To simplify the final cell product that is transplanted and to minimize potential adverse effects, our research has focused on the development of stable 3D constructs that are substrate and scaffold-free and can be cultured in standard cell culture medium. We recently reported two 3D spheroid culture systems: floating liquid marbles and the naked liquid marbles150,151. In the naked liquid marble system, OECs cultured within a liquid drop on a superhydrophobic surface can form spheroids within hours. This rapid formation of spheroids is advantageous as short-term cultured OECs have better effects on the neural survival and axonal growth 152 . Furthermore, we could customize the size of the spheroid using vibration at different frequencies 153 or by changing cell density.
A major advantage of culturing cells in 3D spheres is that it closely mimics the in vivo environment and can recapitulate the cellular interactions and cell-matrix interactions. Importantly, our ability to culture OECs in 3D in this naked liquid marble system revealed two critical attributes of this process: (1) unrestricted movement of cells within liquid marbles enabled natural arrangement of cells reminiscent of their in vivo organization and (2) cells retained their migration properties from spheroids when transferred to a two-dimensional culture plate. Due to the naked liquid marble system resulting in 3D cell constructs that closely mimic the in vivo environment, it is suitable for a range of in vitro studies of OECs which may better reflect cell function and responses.
3D bioprinting is a bespoke approach to address the variable nature of SCIs wherein personalized tissue scaffolds suitable to match an individual’s injury site can be generated. For instance, Joung et al. 154 reported a 3D spinal cord tissue-like platform where multiple neural progenitor cells could be placed within a printed scaffold. More recently, a novel bioink containing hydroxypropyl chitosan, thiolated hyaluronic acid, vinyl sulfonated hyaluronic acid, and matrigel was used for the fabrication of a tissue scaffold to mimic the white matter of spinal cord 155 . The feasibility of printing primary cultured OECs was demonstrated by Othon et al. 156 , where using biological laser printing several lines of OECs could be printed through a multilayer hydrogel scaffold.
In summary, integration of emerging technologies such as 3D bioprinting in combination with scaffold-free models has the potential to create highly complex environments for the recreation of cellular and transplantation niches thereby facilitating the use of predictive and biologically relevant in vitro models.
Conclusion
The microenvironment of the injured spinal cord is unfavorable for the survival of transplanted cells. In this review, we have discussed potential strategies to precondition and stimulate OECs for transplantation to improve their survival and to enhance their therapeutic potential (Fig. 2). When cells are isolated from their native environment, expanded in vitro, and then transplanted back in vivo to a harsh injury environment, the therapeutic potency of the cells is not well-preserved, possibly due to changes in the microenvironment of the cells. Preconditioning OECs in vitro may improve their migration, phagocytic, and immunomodulatory abilities. Understanding how the manipulation of different stimuli, such as oxygen levels, signaling cues, and 3D culture parameters of cells, can affect the behavior of OECs should be a consideration in the design of cell transplantation therapies. Future studies should focus on the development of robust in vitro models that can activate and retain biological properties of the cells by mimicking conditions of the tissue-specific microenvironment. This will help to improve the overall reliability of cell-based therapies and to unlock the therapeutic capabilities of OECs for neural repair.

Schematic overview of the different strategies to improve cells pretransplantation. Olfactory ensheathing cells are isolated and purified from biopsies of olfactory mucosa or olfactory bulb tissue. The cells can be modulated by exposure to low oxygen, stimulated to improve migratory and phagocytic properties, and cultured in three-dimensional constructs prior to transplantation at the site of spinal cord injury.
Footnotes
Acknowledgements
We thank Yasmin Arena-Foster for proof-reading the manuscript.
Ethical Approval
This study was approved by our institutional review board.
Statement of Human and Animal Rights
This article does not contain any studies with human or animal subjects.
Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Clem Jones Foundation grant to JASJ and JAKE; a Motor Accident Insurance Commission of Queensland grant to JASJ, JAKE, and MM; a National Health and Medical Research Council Grant to JASJ and JAKE (APP1183799); and a Perry Cross Foundation Grant to JAKE and JASJ.
